Erratum: Cell Surface CD74-MIF Interactions Drive Melanoma Survival in Response to Interferon-γ

Journal of Investigative Dermatology

Volumn 135, Issue 11, 2015, Pages 2775-2784

  Tanese, Keiji ^a,b   Hashimoto, Yuuri ^a   Berkova, Zuzana ^a   Wang, Yuling ^a   Samaniego, Felipe ^a   Lee, Jeffrey E ^a   Ekmekcioglu, Suhendan ^a   Grimm, Elizabeth A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD74 ANTIGEN; CELL SURFACE PROTEIN; GAMMA INTERFERON; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE B; ISOMERASE; LEUKOCYTE ANTIGEN; MIF PROTEIN, HUMAN; SIALYLTRANSFERASE; ST6GAL1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN INTERACTION; ANIMAL; CELL COMMUNICATION; COMPARATIVE STUDY; DISEASE MODEL; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; NONPARAMETRIC TEST; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIGENS, CD; BLOTTING, WESTERN; CELL COMMUNICATION; CELL LINE, TUMOR; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MELANOMA; MICE; PHOSPHORYLATION; SIALYLTRANSFERASES; SIGNAL TRANSDUCTION; STATISTICS, NONPARAMETRIC;

EID: 84947019270     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.204     Document Type: Article

References (39)

1. Azijli K, Stelloo E, Peters GJ et al. (2014) New developments in the treatment of metastatic melanoma: immune checkpoint inhibitors and targeted therapies. Anticancer Res 34:1493-505
2. Bar-Eli M (1999) Role of interleukin-8 in tumor growth and metastasis of human melanoma. Pathobiology 67:12-8
3. Bedikian AY, Millward M, Pehamberger H et al. (2006) Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24:4738-45
4. Beswick EJ, Bland DA, Suarez G et al. (2005) Helicobacter pylori binds to CD74 on gastric epithelial cells and stimulates interleukin-8 production. Infect Immun 73:2736-43
5. Binsky I, Haran M, Starlets D et al. (2007) IL-8 secreted in a macrophage migration-inhibitory factor-and CD74-dependent manner regulates B cell chronic lymphocytic leukemia survival. Proc Natl Acad Sci USA 104: 13408-13
6. Brown TJ, Lioubin MN, Marquardt H (1987) Purification and characterization of cytostatic lymphokines produced by activated human T lymphocytes. Synergistic antiproliferative activity of transforming growth factor beta 1, interferon-gamma, and oncostatin M for human melanoma cells. J Immunol 139:2977-83
7. Cao ZA, Moore BB, Quezada D et al. (2000) Identification of an IFN-gamma responsive region in an intron of the invariant chain gene. Eur J Immunol 30:2604-11
8. Dunn GP, Koebel CM, Schreiber RD (2006) Interferons, immunity and cancer immunoediting. Nat Rev Immunol 6:836-48
9. Eikawa S, Ohue Y, Kitaoka K et al. (2010) Enrichment of Foxp3+ CD4 regulatory T cells in migrated T cells to IL-6-and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185:6734-40
10. Ekmekcioglu S, Ellerhorst JA, Prieto VG et al. (2006) Tumor iNOS predicts poor survival for stage III melanoma patients. Int J Cancer 119:861-6
11. Ekmekcioglu S, Mumm JB, Udtha M et al. (2008) Killing of human melanoma cells induced by activation of class I interferon-regulated signaling pathways via MDA-7/IL-24. Cytokine 43:34-44
12. Gao J, Bernatchez C, Sharma P et al. (2013) Advances in the development of cancer immunotherapies. Trends Immunol 34:90-8
13. Garbe C, Krasagakis K, Zouboulis CC et al. (1990) Antitumor activities of interferon alpha, beta, and gamma and their combinations on human melanoma cells in vitro: changes of proliferation, melanin synthesis, and immunophenotype. J Invest Dermatol 95:231S-7S
14. Gollob JA, Sciambi CJ, Huang Z et al. (2005) Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-γ. Cancer Res 65:8869-77
15. Gore Y, Starlets D, Maharshak N et al. (2008) Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex. J Biol Chem 283:2784-92
16. Henne C, Schwenk F, Koch N et al. (1995) Surface expression of the invariant chain (CD74) is independent of concomitant expression of major histocompatibility complex class II antigens. Immunology 84:177-82
17. Kushiro K, Chu RA, Verma A et al. (2012) Adipocytes promote B16BL6 melanoma cell invasion and the epithelial-to-mesenchymal transition. Cancer Microenviron 5:73-82
18. Leng L, Chen L, Fan J et al. (2011) A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupusprone NZB/NZW F1 and MRL/lpr mice. J Immunol 186:527-38
19. Meyskens FL Jr, Kopecky KJ, Taylor CW et al. (1995) Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 87:1710-3
20. Nazarian RM, Prieto VG, Elder DE et al. (2010) Melanoma biomarker expression in melanocytic tumor progression: a tissue microarray study. J Cutan Pathol 37(Suppl 1):41-7
21. Oliveira CS, de Bock CE, Molloy TJ et al. (2014) Macrophage migration inhibitory factor engages PI3K/Akt signalling and is a prognostic factor in metastatic melanoma. BMC Cancer 14:630
22. Ong GL, Goldenberg DM, Hansen HJ et al. (1999) Cell surface expression and metabolism of major histocompatibility complex class II invariant chain (CD74) by diverse cell lines. Immunology 98:296-302
23. Pardoll DM (2012) The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 12:252-64
24. Perna D, Karreth FA, Rust AG et al. (2015) BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model. Proc Natl Acad Sci USA 112:E536-45
25. Porter GA, Abdalla J, Lu M et al. (2001) Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes. Ann Surg Oncol 8:116-22
26. Qin Y, Ekmekcioglu S, Liu P et al. (2011) Constitutive aberrant endogenous interleukin-1 facilitates inflammation and growth in human melanoma. Mol Cancer Res 9:1537-50
27. Robert C, Long GV, Brady B et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320-30
28. Roche PA, Marks MS, Cresswell P (1991) Formation of a nine-subunit complex by HLA class II glycoproteins and the invariant chain. Nature 354:392-4
29. Salama AK, Flaherty KT (2013) BRAF in melanoma: current strategies and future directions. Clin Cancer Res 19:4326-34
30. Shi X, Leng L, Wang T et al. (2006) CD44 is the signaling component of the macrophage migration inhibitory factor-CD74 receptor complex. Immunity 25:595-606
31. Spranger S, Spaapen RM, Zha Y et al. (2013) Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. Sci Transl Med 5:200ra116
32. Starlets D, Gore Y, Binsky I et al. (2006) Cell-surface CD74 initiates a signaling cascade leading to cell proliferation and survival. Blood 107: 4807-16
33. Taniguchi K, Petersson M, Hoglund P et al. (1987) Interferon γ induces lung colonization by intravenously inoculated B16 melanoma cells in parallel with enhanced expression of class I major histocompatibility complex antigens. Proc Natl Acad Sci USA 84:3405-9
34. Tibes R, Qiu Y, Lu Y et al. (2006) Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 5: 2512-21
35. Weeraratna AT, Becker D, Carr KM et al. (2004) Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene 23:2264-74
36. Wraight CJ, van Endert P, Moller P et al. (1990) Human major histocompatibility complex class II invariant chain is expressed on the cell surface. J Biol Chem 265:5787-92
37. Zaidi MR, Davis S, Noonan FP et al. (2011) Interferon-γ links ultraviolet radiation to melanomagenesis in mice. Nature 469:548-53
38. Zaidi MR, Merlino G (2011) The two faces of interferon-γ in cancer. Clin Cancer Res 17:6118-24
39. Zikich D, Schachter J, Besser MJ (2013) Immunotherapy for the management of advanced melanoma: the next steps. Am J Clin Dermatol 14:261-72